# Cyclophosphamide as Sole Graft-Versus-Host-Prophylaxis After Allogeneic Stem Cell Transplantation

> **NCT01283776** · PHASE2 · COMPLETED · sponsor: **University of Cologne** · enrollment: 11 (actual)

## Conditions studied

- Multiple Myeloma
- Non-Hodgkin-Lymphoma
- Hodgkin's Disease

## Interventions

- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT01283776
- **Lead sponsor:** University of Cologne
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2013-12
- **Final completion:** 2014-06
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2014-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01283776

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01283776, "Cyclophosphamide as Sole Graft-Versus-Host-Prophylaxis After Allogeneic Stem Cell Transplantation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01283776. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*